Lichen China
LICN
1 hedge funds and large institutions have $30.8K invested in Lichen China in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
2,274% more capital invested
Capital invested by funds: $1.3K → $30.8K (+$29.5K)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $30.8K | +$36K | +133 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$1.3K | -3 | Closed |
|
LICN Hedge Fund Activity: Q1 2024 in Review
1 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q1 2024, worth a combined $30.8K — up 2,274% from $1.3K a quarter earlier.
Fund positioning in LICN was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $36K. The largest seller was UBS Group, exiting entirely with an estimated $1.3K sold.
- 1 institutional investor held Lichen China (LICN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $30.8K of Lichen China stock for Q1 2024, up 2,274% quarter-over-quarter.
- 1 fund opened new Lichen China positions in Q1 2024 and 1 closed out, a net change of 0 holders.
- The largest Lichen China buyer in Q1 2024 was Susquehanna International Group, an estimated $36K added.
- The largest Lichen China seller in Q1 2024 was UBS Group, an estimated $1.3K sold.
Based on aggregated 13F filings for Q1 2024.